Aby J. Mathew Sells 1,597 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 1,597 shares of the firm’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total value of $39,925.00. Following the sale, the executive vice president now directly owns 260,601 shares of the company’s stock, valued at $6,515,025. This represents a 0.61 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

BioLife Solutions Stock Down 0.2 %

BLFS stock opened at $25.00 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of -23.58 and a beta of 2.04. The business’s fifty day moving average price is $26.62 and its two-hundred day moving average price is $25.50. BioLife Solutions, Inc. has a fifty-two week low of $14.84 and a fifty-two week high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.32. The firm had revenue of $22.71 million for the quarter, compared to analysts’ expectations of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same quarter last year, the business earned ($0.21) EPS. On average, equities analysts anticipate that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on BLFS shares. Northland Securities raised their price target on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday, January 8th. HC Wainwright raised their price target on BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Benchmark reaffirmed a “buy” rating and set a $30.00 price target on shares of BioLife Solutions in a report on Thursday, December 19th. Finally, KeyCorp raised their price target on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $29.86.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. State Street Corp raised its stake in BioLife Solutions by 7.3% in the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after purchasing an additional 95,788 shares in the last quarter. Geode Capital Management LLC raised its stake in BioLife Solutions by 2.2% in the third quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock valued at $21,107,000 after purchasing an additional 18,473 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in BioLife Solutions by 40.8% in the third quarter. The Manufacturers Life Insurance Company now owns 19,463 shares of the medical equipment provider’s stock valued at $487,000 after purchasing an additional 5,638 shares in the last quarter. Barclays PLC raised its stake in BioLife Solutions by 20.1% in the third quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock valued at $1,613,000 after purchasing an additional 10,803 shares in the last quarter. Finally, D.A. Davidson & CO. acquired a new position in BioLife Solutions in the third quarter valued at about $1,018,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.